This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
ntrk
NTRK
NTRK1/2/3 encode TrkA/B/C neurotrophin receptors; chromosomal fusions (ETV6-NTRK3 in secretory carcinoma; TPM3-NTRK1 pan-tumor) create constitutively active kinases. Larotrectinib and entrectinib are approved TRK inhibitors with ~75% ORR in NTRK fusion-positive tumors.
Entry Metadata
| Field | Value |
|---|---|
| ID | ntrk |
| Name | NTRK |
| Status | draft |
| Last reviewed | 2026-06-06 |
| Atlas | 01-human |
| Scale | 03-molecular |
Cross-Atlas Connections
Sources
- Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731-739. · PubMed 29466156
- Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours. Lancet Oncol. 2020;21(2):271-282. · PubMed 31838007